Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial

Francis Couturaud, Gilles Pernod, Emilie Presles, Elisabeth Duhamel, Patrick Jego, Karine Provost, Brigitte Pan-Petesch, Claire Bal Dit Sollier, Cécile Tromeur, Clément Hoffmann, Luc Bressollette, Philippe Lorillon, Philippe Girard, Emmanuelle Le Moigne, Aurelia Le Hir, Marie Guégan, Silvy Laporte, Patrick Mismetti, Karine Lacut, Jean-Luc Bosson, Laurent Bertoletti, Oliver Sanchez, Guy Meyer, Christophe Leroyer, Dominique Mottier, “PADIS-DVT” investigators, Francis Couturaud, Gilles Pernod, Emilie Presles, Elisabeth Duhamel, Patrick Jego, Karine Provost, Brigitte Pan-Petesch, Claire Bal Dit Sollier, Cécile Tromeur, Clément Hoffmann, Luc Bressollette, Philippe Lorillon, Philippe Girard, Emmanuelle Le Moigne, Aurelia Le Hir, Marie Guégan, Silvy Laporte, Patrick Mismetti, Karine Lacut, Jean-Luc Bosson, Laurent Bertoletti, Oliver Sanchez, Guy Meyer, Christophe Leroyer, Dominique Mottier, “PADIS-DVT” investigators

Abstract

The optimal duration of anticoagulation after a first episode of unprovoked deep-vein thrombosis is uncertain. We aimed to assess the benefits and risks of an additional 18 months of treatment with warfarin versus placebo, after an initial 6 months of anticoagulation for a first unprovoked proximal deep-vein thrombosis. We conducted a multicenter, randomized, double-blind, controlled trial comparing an additional 18 months of warfarin with placebo in patients with a unprovoked proximal deep-vein thrombosis initially treated for 6 months (treatment period: 18 months; follow up after treatment period: 24 months). The primary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months. Secondary outcomes were the composite at 42 months, as well as each component of the composite, and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 months. All outcomes were centrally adjudicated. A total of 104 patients, enrolled between July 2007 and October 2013 were analyzed on an intention-to-treat basis; no patient was lost to follow-up. During the 18-month treatment period, the primary outcome occurred in none of the 50 patients in the warfarin group and in 16 out of 54 patients (cumulative risk, 29.6%) in the placebo group (hazard ratio, 0.03; 95% confidence interval: 0.01 to 0.09; P<0.001). During the entire 42-month study period, the composite outcome occurred in 14 patients (cumulative risk, 36.8%) in the warfarin group and 17 patients (cumulative risk, 31.5%) in the placebo group (hazard ratio, 0.72; 95% confidence interval: 0.35-1.46). In conclusion, after a first unprovoked proximal deep-vein thrombosis initially treated for 6 months, an additional 18 months of warfarin therapy reduced the composite of recurrent venous thrombosis and major bleeding compared to placebo. However, this benefit was not maintained after stopping anticoagulation. Clinical registration: this trial was registered at www.clinicaltrials.gov as #NCT00740493.

Copyright© 2019 Ferrata Storti Foundation.

Figures

Figure 1.
Figure 1.
Patients’ flow through the study.
Figure 2.
Figure 2.
Kaplan-Meier estimates of the probability of the composite outcome of recurrent venous thromboembolism and major bleeding during the entire study period, according to study group. The unadjusted hazard ratios (95% confidence interval) warfarin/placebo were 0.03 (0.01 to 0.51) during the treatment period and 0.72 (0.35 to 1.46) during the entire study period.
Figure 3.
Figure 3.
Meta-analysis of the PADIS-PE and PADIS-DVT studies. Pooled hazard ratios were calculated for the composite of recurrent venous thromboembolism and major bleeding and for the recurrent venous thromboembolism component. The pooled hazard ratio for the component of major bleeding is not reported as there was no major bleeding in the placebo group of the PADIS-DVT trial. HR: hazard ratio; 95% CI: 95% confidence interval; PE: pulmonary embolism; DVT: deep-vein thrombosis.

References

    1. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340(8824): 873–876.
    1. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep-vein thrombosis. Thromb Haemost. 1995;74(2):606–611.
    1. Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332(25):1661–1665.
    1. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901-907. Erratum in: N Engl J Med. 1999;341(4):298.
    1. Agnelli G, Prandoni P, Santamaria MG, et al. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001;345(3):165–169.
    1. Agnelli G, Prandoni P, Becattini C, et al. Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139(1):19–25.
    1. Couturaud F, Sanchez O, Pernod G, et al. PADIS-PE investigators. six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA. 2015;314(1):31–40.
    1. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
    1. Kearon C, Ginsberg JS, Kovacs MJ, et al. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–639.
    1. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
    1. Weitz JI, Lensing AWA, Prins MH, et al. EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–1222.
    1. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.
    1. Schulman S, Kearon C, Kakkar AK, et al. REMEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8): 709–718.
    1. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578–589.
    1. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036.
    1. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279(6):458–462.
    1. Lecumberri R, Alfonso A, Jiménez D, et al. RIETE Investigators. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost. 2013;110(4):834–843.
    1. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998;128(8):663-677. Erratum in: Ann Intern Med. 1998;129(5):425.
    1. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10):1037–1052.
    1. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med. 2008;359(26):2804–2813.
    1. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239.
    1. Mismetti P, Baud JM, Becker F, et al. Agence française de sécurité sanitaire des produits de santé. [Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients]. J Mal Vasc. 2010;35(3):127–136.
    1. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013;122(5):817–824.
    1. Baglin T, Bauer K, Douketis J, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep-vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2012;10(4):698–702.
    1. Kearon C, Akl EA. Duration of anticoagulant therapy for deep-vein thrombosis and pulmonary embolism. Blood. 2014;123(12): 1794–801.
    1. Rodger MA, Le Gal G, Anderson DR, et al. REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться